Tafenoquine study in healthy Papua New Guinean children
Part of Infections clinical trials.
This study tests how the malaria medicine tafenoquine works in healthy children in Papua New Guinea. It may help find the right dose to prevent malaria safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Normal G6PD enzyme activity (above 70%)
- No current malaria infection
- No malaria medicine taken in the last 4 weeks
- No allergy to primaquine
- Able to attend all study visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called tafenoquine, which is used to treat malaria. It aims to see how well it works in children with uncomplicated malaria, and participants will also receive standard malaria treatments.
This study tests a medicine given to mothers after childbirth to see how it passes into breast milk and if it is safe for babies. It may help prevent malaria relapse in mothers who have had vivax malaria.
This study tests how the malaria medicine tafenoquine is processed in the bodies of young children with vivax malaria. It helps find the right dose for small children and ensures the treatment is safe and effective.
This study tests how a new malaria drug called tafenoquine moves through the body in healthy adults. It helps provide important safety and dosing information for future use.
This trial tests a revised dose of a medicine called tafenoquine to more effectively cure vivax malaria (a type of malaria that can come back). It is for people with normal G6PD enzyme levels and a current fever from vivax malaria.
This study tests the best dose of tafenoquine to treat people with symptoms from a malaria type called P. vivax and to help prevent it from coming back. You may be eligible if you recently had fever and meet specific blood and safety checks, especially G6PD level.
Hear when a new Pharmacokinetics of Tafenoquine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.